Integrilin is a GP IIb/IIIa blocker indicated for acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI), including those undergoing intracoronary stenting.
Integrilin reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, it inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner.
Teva’s Eptifibatide Injection is already available as a 0.75mg/mL, 75mg strength. The new strength is available as 10mL single-use vials.
For more information call (888) 838-2872 or visit TevaGenerics.com.